Journal

Wegovy Pill (semaglutide) vs. Foundayo (orforglipron) for Weight Loss

The U.S. Food and Drug Administration has now approved two once-daily oral GLP‑1–pathway therapies for chronic weight management: Wegovy pill (oral semaglutide 25 mg, peptide-based) from Novo Nordisk and Foundayo (orforglipron, non‑peptide small molecule) from Eli Lilly and Company. Wegovy pill was approved in late December 2025 with launch in early January 2026, while Foundayo was approved April 1, 2026 via an ultra‑accelerated pathway tied to a national-priority voucher pilot.

Read More »

Peptides & Cellular Optimizers

Compounds that unlock what your body can do Recovery. Performance. Longevity. The cutting edge of wellness, delivered to your door. Athletes use them. Biohackers swear

Read More »
ED in the 21st Century

ED in the 21st Century

Between student loans, social media pressure, and 8+ hours of daily screen time, modern life has created a perfect storm for sexual health issues in young men. But here’s the thing: while the 21st century created new challenges, it also gave us better tools to address them than any previous generation.

Read More »

Pentadecapeptide (PDA)

This next-generation recovery peptide is gaining attention as an improved version of BPC-157, offering better stability and enhanced tissue repair for muscles, tendons, and ligaments. While many guys accept chronic pain and slow recovery as “part of getting older,” PDA users are reporting faster healing from workouts, reduced inflammation in problem areas, and improvement in nagging injuries that won’t go away.

Read More »